Day: May 16, 2022

scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

FDA assigns PDUFA action date of October 8, 2022 Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved Ended Q1 with cash, cash equivalents, restricted cash and investments of $65.6 million BURLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today reported financial results for the first quarter ended March 31, 2022 and provided a business update. Business UpdateAnnounced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) resubmission for FUROSCIX, a proprietary formulation...

AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

– First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as clinical potential with checkpoint inhibitors – On track to commence Phase 2 study for lead program of Ampligen for pancreatic cancer Q3 2022 – Focus on further advancement of oncology pipeline and well-positioned to achieve multiple clinical and regulatory value-driving milestones throughout 2022 – Cash position of $44.5 million expected to fund company through the end of 2023 OCALA, Fla., May 16, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused...

Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

– Transformational quarter for Novan, marked by acquisition of EPI Health – – Strongest quarter in total prescriptions for Rhofade increasing 47% from Q1 2021 – – Ongoing activities toward submission of first New Drug Application (NDA) for berdazimer gel, 10.3% (SB206), targeted before the end of 2022 – DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the first quarter ended March 31, 2022 and provided a corporate update. The Company will host a conference call and webcast, today, May 16, 2022, at 8:30 a.m. ET (details below). “The first quarter of 2022 represented a foundational leap forward for Novan and its shareholders. With the acquisition of EPI Health on March 11th, we are now a fully integrated medical dermatology...

Lottery.com Announces Strong First Quarter Results

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

First quarter 2022 revenue of $21.2 million, up $15.7 million from the prior-year period First quarter 2022 gross profit of $18.0 million, up $15.5 million from the prior-year period First quarter 2022 net loss of $15.8 million, Adjusted EBITDA of $7.7 million1 AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) — Lottery.com Inc. (Nasdaq: LTRY, LTRYW) (“Lottery.com” or the “Company”), a leading technology company that is transforming how, where and when the lottery is played, reported financial results for the first quarter ended March 31, 2022. Tony DiMatteo, Lottery.com Co-Founder and CEO, commented, “I’m pleased with our first quarter results and the team’s continued focus on our core business and generating strong Adjusted EBITDA. Once again, LotteryLink has demonstrated its ability to contribute to our top and bottom line growth...

Triterras Announces Settlement Agreement in Securities Class Action Litigation

Written by Customer Service on May 16, 2022. Posted in Public Companies.

SINGAPORE, May 16, 2022 (GLOBE NEWSWIRE) — Triterras Inc. (OTC Expert Market: TRIRF) (“Triterras” or the “Company”), a leading fintech company focused on trade and trade finance, announced today that Triterras and all defendants in the class action Erlandson v. Triterras, Inc., et al. (Civil Action No. 7:20-cv-10795-CS (S.D.N.Y.) (the “Action”)), have entered into a settlement agreement to fully and completely resolve the Action. The settlement is not an admission of wrongdoing, fault or liability. Under the terms of the Stipulation and Agreement of Settlement (“Settlement Agreement”), which has been filed with the Court, Triterras will pay $9 million, of which a portion will be covered by insurance. The Settlement Agreement is subject to approval by the Court and the fulfillment of other conditions set forth therein, all of which...

REPEAT – TAAT® Files Patent Application for Inclusion of Zero-Hemp Cannabinoid-Free Biomass in Beyond Tobacco™ Product Line for Expanded Global Markets

Written by Customer Service on May 16, 2022. Posted in Public Companies.

Picture 1 To expand its Total Addressable Market in the USD $812 billion global tobacco industry, the Company has developed and filed an expedited U.S. patent for a zero-hemp formulation of the Beyond Tobacco™ base material of TAAT®. A sample TAAT® stick made with the zero-hemp formulation is shown in the image above.As global demand for TAAT® has grown since its first U.S. launch in December 2020, the Company has engineered a variation of its Beyond Tobacco™ base material using reconstituted plant-based materials for international markets to which the current hemp-based formulation cannot be imported due to its CBD and negligible THC content. To capitalize on this global opportunity, TAAT® has filed an expedited U.S. patent covering this expanded scope of base materials in addition to proprietary integrations with smartphones and...

Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Written by Customer Service on May 16, 2022. Posted in Public Companies.

WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright Global Investment Conference, which will be available beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET. Management will be available May 23rd throughout the day for virtual 1×1 meetings. A webcast of the presentation may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical...

Ascot Reports First Quarter 2022 Results, Announces New Management Hire, and Commences Underground Development at the Premier Gold Project

Written by Customer Service on May 16, 2022. Posted in Public Companies.

Figure 1 S1 Portal face being preparedFigure 2 First portal blast takenFigure 3 Portal developmentFigure 4 Portal development continuingFigure 5 Mill building interior showing Ball and SAG mills with motors installedFigure 6 Tailings thickener foundation construction and cyanide destruction tank padsFigure 7 New clarifier pad foundation constructionVANCOUVER, British Columbia, May 16, 2022 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company”) is pleased to announce the Company’s unaudited financial results for the three months ended March 31, 2022 (“Q1 2022”). Ascot also announces the hiring of Bryant Schwengler as Vice President, Operations and General Manager, and as previously planned has commenced underground development work at the Company’s Premier Gold Project (“PGP”...

Next Hydrogen Reports Q1 2022 Financial Results

Written by Customer Service on May 16, 2022. Posted in Public Companies.

MISSISSAUGA, Ontario, May 16, 2022 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen“) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the first quarter ended March 31, 2022. “The buildout and installation of our multi-platform test infrastructure in the first quarter was a huge milestone towards the Company’s product development roadmap,” said Raveel Afzaal, President and CEO of Next Hydrogen. “In addition, our new relationships with Black & Veatch and the New York State Energy Research and Development Authority, puts Next Hydrogen in an excellent position to participate in future large-scale multi-megawatt green hydrogen solutions.” Q1 2022 Financial HighlightsRevenue was $40,795 for the three-month period, compared to $NIL...

Hot Melt Adhesives Market to Worth USD 10.10 Billion by 2029 | Hot Melt Adhesives Industry CAGR of 5.2% by (2022-2029)

Written by Customer Service on May 16, 2022. Posted in Mergers And Acquisitions.

Companies covered in hot melt adhesives market are Exxon Mobil Corporation (U.S.) Dow Inc. (U.S.) 3M (U.S.) Henkel AG & Co. KGaA (Germany) MELER (Navarra) Sanyhot Adhesivos, S.A. (Spain) TEX YEAR INDUSTRIES INC. (Taiwan) H.B. Fuller Company (U.S.) Arkema Group (U.S.) Sika AG (Switzerland) Bostik (U.S.) Jowat SE (U.S.) AVERY DENNISON CORPORATION (U.S.) LyondellBasell Industries Holdings B.V. (Netherlands) Embagrap SA (Spain) and many more Pune, India, May 16, 2022 (GLOBE NEWSWIRE) — The global hot melt adhesives market size was USD 6.69 billion in 2021 and reached USD 7.10 billion in 2022. The market is expected to reach USD 10.10 billion by 2029, exhibiting a CAGR of 5.2% during the forecast period. The rising demand for improved and strong products and extensive adoption of online shopping may foster the market development....

Day: May 16, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals